Clinical Feed
Comment on Revised ISHAM-ABPA Guidelines for Diagnosing and Treating ABPA/Mycoses
Comment on diagnostic criteria for ABPA/Mycoses proposed by ISHAM, with context on Aspergillus fumigatus sensitisation and ABPA progression in adult asthma patients.
- Published: 02 Apr 2026, 07:18 am (UTC)
- Updated: 02 Apr 2026, 07:18 am (UTC)
- Specialty: Critical Care
- Source: European Respiratory Journal
GIST
Extract We read with great interest the diagnostic criteria for allergic bronchopulmonary aspergillosis/mycoses (ABPA/M) proposed by the International Society for Human and Animal Mycology (ISHAM) working group [1], that was recently published in the European Respiratory Journal . A garwal et al . [2] reported that Aspergillus fumigatus sensitisation affects up to 25% of adult asthmatic patients presenting to tertiary care centres, with nearly 37% of sensitised individuals progressing to ABPA.
Clinical Editorial
European Respiratory Journal published a clinical update in Critical Care on 02 Apr 2026. The item focuses on Comment on: Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. Review the original article for the full source wording and details.
Original source: http://erj.ersjournals.com/cgi/content/short/67/4/2501724?rss=1